NASDAQ:SOPH - SOPHiA Genetics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.00
  • Forecasted Upside: 59.17 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$14.45
▲ +0.35 (2.48%)

This chart shows the closing price for SOPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New SOPHiA Genetics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SOPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SOPH

Analyst Price Target is $23.00
▲ +59.17% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for SOPHiA Genetics in the last 3 months. The average price target is $23.00, with a high forecast of $24.00 and a low forecast of $22.00. The average price target represents a 59.17% upside from the last price of $14.45.

This chart shows the closing price for SOPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in SOPHiA Genetics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/15/2021CowenInitiated CoverageOutperformHigh
8/17/2021CowenInitiated CoverageOutperformHigh
8/17/2021JPMorgan Chase & Co.Initiated CoverageOverweight$23.00High
8/17/2021Morgan StanleyInitiated CoverageOverweight$24.00High
8/17/2021Credit Suisse GroupInitiated CoverageOutperform$22.00High
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.24 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/28/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
SOPHiA Genetics logo
SOPHiA GENETICS SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM(TM) Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. SOPHiA GENETICS SA is based in BOSTON.
Read More

Today's Range

Now: $14.45
Low: $14.00
High: $14.65

50 Day Range

MA: $15.91
Low: $14.00
High: $18.80

52 Week Range

Now: $14.45
Low: $13.76
High: $19.80

Volume

30,664 shs

Average Volume

98,590 shs

Market Capitalization

$915.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of SOPHiA Genetics?

The following equities research analysts have issued stock ratings on SOPHiA Genetics in the last year: Cowen Inc, Credit Suisse Group AG, JPMorgan Chase & Co., and Morgan Stanley.
View the latest analyst ratings for SOPH.

What is the current price target for SOPHiA Genetics?

3 Wall Street analysts have set twelve-month price targets for SOPHiA Genetics in the last year. Their average twelve-month price target is $23.00, suggesting a possible upside of 59.2%. Morgan Stanley has the highest price target set, predicting SOPH will reach $24.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $22.00 for SOPHiA Genetics in the next year.
View the latest price targets for SOPH.

What is the current consensus analyst rating for SOPHiA Genetics?

SOPHiA Genetics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SOPH will outperform the market and that investors should add to their positions of SOPHiA Genetics.
View the latest ratings for SOPH.

How do I contact SOPHiA Genetics' investor relations team?

The company's listed phone number is 41-21-694-1060. The official website for SOPHiA Genetics is www.sophiagenetics.com.